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Introduction 107 
Allergic rhinitis is the most common clinical presentation of allergy, affecting 400 million people 108 
worldwide, and with increasing incidence in westernized countries.1,2 To elucidate the genetic 109 
architecture and understand disease mechanisms of allergic rhinitis, we carried out a meta-110 
analysis of allergic rhinitis in 59,762 cases and 152,358 controls of European ancestry and 111 
identified a total of 41 risk loci for allergic rhinitis, including 20 loci not previously associated with 112 
allergic rhinitis, which were confirmed in a replication phase of 60,720 cases and 618,527 113 
controls. Functional annotation implied genes involved in various immune pathways, and fine 114 
mapping of the HLA region suggested amino acid variants of importance for antigen binding. 115 
We further performed GWASs of allergic sensitization against inhalant allergens and non-116 
allergic rhinitis suggesting shared genetic mechanisms across rhinitis-related traits. Future 117 
studies of the identified loci and genes might identify novel targets for treatment and prevention 118 
of allergic rhinitis.   119 
 120 
Main text 121 
Allergic rhinitis (AR) is an inflammatory disorder of the nasal mucosa mediated by allergic 122 
hypersensitivity responses to environmental allergens1 with large adverse effects on quality of 123 
life and health care expenditures. The underlying causes for AR are still not understood and 124 
prevention of the disease is not possible. The heritability of AR is estimated to be more than 125 
65%3,4. Seven loci have been associated with allergic rhinitis in genome-wide association 126 
studies (GWAS) of AR per se, while other have been suggested from GWAS studies on related 127 
traits, such as self-reported allergy, asthma plus hay fever, or allergic sensitization5–9, but only 128 
few of these have been replicated. 129 
We carried out a large-scale meta-GWAS of AR including a discovery meta-analysis of 130 
16,531,985 genetic markers from 18 studies comprising 59,762 cases and 152,358 controls of 131 
primarily European ancestry (Supplementary Table 1, cohort recruitment details in 132 
Supplementary Note). We report the genetic heritability on the liability scale of AR as at least 133 
7.8% (assuming 10% disease prevalence), with a genomic inflation of 1.048 (Supplementary 134 
Figure 1). We identified 42 genetic loci, with index markers below genomewide significance 135 
(p<5e-8), of which 21 have previously been reported in relation to AR or other inhalant allergy6–9 136 
(Fig. 1, Table 1, Table 2, Supplementary Fig. 2, Supplementary Fig. 3).  137 
One study (23andMe) had a proportionally large weight (~80%) in the discovery phase. 138 
Overall there was good agreement between 23andMe and the other studies with respect to 139 
effect size and direction, and regional association patterns (Supplementary Table 2 and 140 
Supplementary Fig. 4+5), and the genetic correlation was 0.80 (p<2e-17). Heterogeneity 141 
between 23andMe and the remaining studies was statistically significant (p<0.05) for 7 of 42 142 
loci, in most cases due to a smaller effect size in 23andMe. This was likely due to many non-143 
23andMe studies using a more robust phenotype definition of doctor diagnosed AR 144 
(Supplementary Table 3), which tended to result in larger effect sizes (Supplementary Table 145 
4).  146 
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  The index markers from a total of 25 loci that had not previously been associated with 147 
AR or other inhalant allergy were carried forward to the replication phase. These included 16 148 
loci that showed genome-wide significant association in the discovery phase and evidence of 149 
association (p<0.05) in both 23andMe and non-23andMe studies (Supplementary Table 2), 150 
and an additional 9 loci that were selected from the p-value stratum between 5e-8 and 1e-6 151 
based on enrichment of gene sets involved in immune-signaling (Supplementary Table 5). 152 
Replication was sought in another 10 studies with 60,720 cases and 618,527 controls. Of the 25 153 
loci, 20 loci reached a Bonferroni-corrected significance threshold of 0.05 (p<0.0019) in a meta-154 
analysis of replication studies (Fig. 1 (blue), Table 2), and all of these reached genome-wide 155 
significance in the combined fixed-effect meta-analysis of discovery and replication studies 156 
(Table 2). Evidence of heterogeneity was seen for one of these loci (rs1504215), which did not 157 
reach statistical significance in the random effects model (0.95 [0.92; 0.97], p=2.83e-07, 158 
Supplementary Fig. 3).  159 
 A conditional analysis of top loci identified 13 additional independent variants at p<1e-5, 160 
with 4 of these being genome-wide significant (near WDR36, HLA-DQB1, IL1RL1 and LPP) 161 
(Supplementary Table 6 and Supplementary Fig. 5, bottom panel). 162 
To gain insight into functional consequences of known and novel loci, we utilized a 163 
number of data sources, including 1) 11 eQTL sets and 1 meQTL set from blood and blood 164 
subsets; 2) 2 eQTL sets and 1 meQTL set from lung tissue; and 3) data on enhancer-promoter 165 
interactions in 15 different blood subsets. Support of regulatory effects on coding genes was 166 
found for 33 out of the 41 loci. Many loci showed evidence of regulatory effects across a wide 167 
range of immune cell types (including B- and T-cells), while other seemed cell type-specific 168 
(Supplementary Table 7). Calculation of the “credible set” of markers for each locus using a 169 
Bayesian approach that selects markers likely to contain the causal disease-associated markers 170 
(Supplementary Table 8) and looking up these in the Variant Effect Predictor database 171 
generated a list of 17 markers producing amino acid changes, including deleterious changes in 172 
NUSAP1, SULT1A1 and PLCL, as predicted by SIFT (Supplementary Table 9). 173 
The major histocompatibility complex (MHC) on chr6p harbored some of the strongest 174 
association signals in the GWAS with independent signals located around HLA-DQB and HLA-175 
B, respectively. The top variant at HLA-DQB was an eQTL for several HLA-genes, including 176 
HLA-DQB1, HLA-DQA1, HLA-DQA2, and HLA-DRB1 in immune and/or lung tissue, and the top 177 
variant at HLA-B was an eQTL for MICA (Supplementary Table 7). In addition we found 178 
associations with several classical HLA alleles, including HLA-DQB1*02:02, HLA-DQB1*03:01, 179 
HLA-DRB1*04:01, and HLA-C*04:01, which were in weak LD (r2<0.1) with the GWAS top SNPs 180 
(Supplementary Tables 10 and 11), and strong associations with well imputed amino acid 181 
variants, including HLA-DQB1 His30 (p=2.06e-28, OR=0.91) and HLA-B AspHisLeu116 182 
(p=6.00e-13, OR=1.06) (Supplementary Tables 12 and 13). Within HLA-DQB1, the amino acid 183 
variant was in moderate LD (r2=0.71) with the GWAS top SNP and accounted for most of the 184 
SNP association (rs34004019, p=2.18e-28, OR=0.88, conditional p-value=1.35e-03). Within 185 
HLA-B, the strongest associated amino acid variant was only in weak LD (r2=0.23) with the top 186 
SNP and accounted for a small part of the SNP association (rs2428494, p=3.99e-15, OR=1.07, 187 
conditional p-value=3.23e-10 ). Importantly, the strongest associated amino acid variants in 188 
HLA-DQB1 and HLA-B, respectively were both located in the peptide binding pockets with a 189 
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high likelihood of affecting MHC-peptide interaction (Figure 2). MHC class II molecules, 190 
including HLA-DQ, are known for their role in allergen-binding and Th2 driven immune 191 
responses10 and our results therefore suggest that the GWAS signal at this locus involves 192 
structural changes related to allergen binding properties. This might be in addition to  gene 193 
regulatory effects similar to what has been found for autoimmune disease.11,12 194 
The majority of the 20 loci not previously associated with AR per se imply genes with a known 195 
role in the immune system, including IL7R13, 14, SH2B315, CEBPA/CEBPG16, 17, CXCR518, 196 
FCER1G, NFKB119, BACH220, 21, TYRO322, LTK 23, VPRBP24, SPPL325, OASL26, RORA27, and 197 
TNFSF1128. Other loci imply genes with no clear function in AR pathogenesis. These include 198 
one of the strongest associated loci in this meta-analysis at 12q24.31 with the top-signal located 199 
between CDK2AP1 and C12orf65, harboring cis-eQTLs in blood and lung tissue for several 200 
genes and evidence for enhancer-promoter interaction with DDX55 in various immune cells. 201 
(Supplementary Table 14 and further locus description in the Supplementary Note). 202 
Concomitantly with the current study, a GWAS combining asthma, eczema and AR was 203 
conducted.29 The majority (15/20) of identified AR loci in our study were also suggested in the 204 
previous, more unspecific, GWAS29 (as indicated in Table  2), while many suggested loci from 205 
the previous GWAS were not identified in our study. Asthma, eczema and allergic rhinitis are 206 
related but distinct disease entities, often with seperate disease mechanisms, e.g. allergic 207 
sensitization is present in only 50% of children with asthma30 and 35% of children with 208 
eczema.31 Our results therefore complement those from the less specific “atopic phenotype” 209 
GWAS29 by pinpointing loci specifically associated, and replicated, in relation to allergic rhinitis.   210 
AR loci were significantly enriched (p<1e-5) for variants reported to be associated with 211 
autoimmune disorders. Reported autoimmune variants were located within a 1mb distance of 31 212 
(76%) of the 41 AR loci. For 24 of these, an autoimmune top SNP was also associated with AR, 213 
and for 12 of these the autoimmune top SNP was in LD (r2>0.5) with the AR top SNP 214 
(Supplementary Table 15). For approximately half of these, the direction of effect was the 215 
same for the autoimmune and AR top SNP in line with a previous study,32 underlining the 216 
complex genetic relationship between AR and autoimmunity, which might involve shared as well 217 
as diverging molecular mechanisms.  218 
Assessment of enrichment of AR-associated variant burden in open chromatin as 219 
defined by DNAse hypersensitive sites showed a clear enrichment in several blood and immune 220 
cell subsets, with the largest enrichment in T-cells (CD3 expressing), B-cells (CD19 expressing), 221 
and T and NK-cells (CD56-expressing) (Fig. 3, Supplementary Table 16, Supplementary Fig. 222 
6). We also probed tissue enrichment by means of gene expression data from a wide number of 223 
sources, showing enrichment of AR genes in blood and immune cell subsets, as well as in 224 
tissues of the respiratory system, including oropharynx, respiratory and nasal mucosa 225 
(Supplementary Table 17).  226 
To explore biological connections and identify new pathways associated with AR, we 227 
combined all genes suggested from eQTL/meQTL analyses, enhancer-promoter interactions 228 
and localization within the top loci. The resultant prioritized gene set consisted of 255 genes, of 229 
which 89 (~36%) were present in more than one set (Supplementary Fig. 7). Overall, the full 230 
set was enriched for pathways involved in Th1 and Th2 Activation (Fig. 4), antigen presentation, 231 
cytokine signaling, and inflammatory responses (Supplementary Table 18).    232 
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Using the 255 prioritized genes in combination with STRING to identify proteins that 233 
interact with the proteins encoded by the high priority genes, we demonstrated a high degree of 234 
interaction at the protein level, and several of these proteins are target of approved drugs or 235 
drugs in development, including TNFSF11, NDUFAF1, PD-L1, IL-5, and IL-13  (Fig. 4).  236 
AR is strongly correlated to allergic sensitization (presence of allergen-specific IgE), but 237 
sensitization is often present without AR suggesting specific mechanisms determining 238 
progression from sensitization to disease. We therefore conducted a GWAS on sensitization to 239 
inhalant allergens (AS) comprising 8,040 cases and 16,441 controls from 13 studies 240 
(Supplementary Table 1), making it the largest GWAS on allergic sensitization to date7. A total 241 
of 10 loci reached genome-wide significance, including one novel hit near the FASLG gene 242 
(Supplementary Table 19). The genetic heritability on the liability scale was 17.75% (10% 243 
prevalence), considerably higher than the heritability of AR in consistency with a more 244 
homogeneous phenotype. Look-up of AR top-loci in the AS GWAS demonstrated large 245 
agreement with 40 of the 41 AR markers showing same direction of effect and 28 also showing 246 
nominal significance for AS (Supplementary Table 20). This suggests that AR and AS share 247 
biological mechanisms and that AS loci generally affect systemic allergic sensitization. We 248 
compared genetic pathways of AR and AS using the DEPICT tool showing overlap in enriched 249 
pathways but also differences among the top gene sets, with AR gene sets characterized by B-250 
cell, Th2, and parasite responses and AS gene sets characterized by a broader activation of 251 
cells (Supplementary Fig 8 and Supplementary Tables 21 and 22).  252 
Non-allergic rhinitis, defined as rhinitis symptoms without evidence of allergic 253 
sensitization, is a common but poorly understood disease entity.33 We performed the first 254 
GWAS on this phenotype hypothesizing that this might reveal specific rhinitis mechanisms. The 255 
analysis included 2,028 cases and 9,606 controls from 9 studies but did not identify any risk loci 256 
at the genome-wide significance level. Comparison with AR results suggested some overlap in 257 
susceptibility loci (Supplementary Note and Supplementary Table 23).  258 
We estimated the proportion of AR in the general population that can be attributed to the 259 
41 identified AR loci and obtained a conservative population-attributable risk fraction estimate of 260 
39% (95% CI 26%-50%), considering the 10% of the population with the lowest genetic risk 261 
scores to represent an ‘unexposed’ group. Allergic rhinitis prevalence plotted by genetic risk 262 
score (Supplementary Fig. 9) showed approximately 2 times higher prevalence in the 7% of 263 
the population with the highest risk score compared to the 7% with the lowest risk score.   264 
Finally, we investigated the genetic correlation of AR with AS, asthma34, and eczema35 265 
by LD score regression. There was a strong correlation between AR and AS (r2=0.73, p<2e-34), 266 
moderate with asthma (r2=0.60, p<3e-14) and weaker with eczema (r2=0.40, p<2e-07). 267 
The identified AR loci were tested for association with AR in non-European cohorts, only 268 
showing nominal significant association for a loci, but this analysis had limited statistical power 269 
due to population sizes (Supplementary Table 24).   270 
In conclusion, we expanded the number of established susceptibility loci for AR and 271 
highlighted involvement of AR susceptibility loci in diverse immune cell types and both innate 272 
and adaptive IgE-related mechanisms. Future studies of novel AR loci might identify targets for 273 
treatment and prevention of disease. 274 
 275 
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Figure legends 391 
Figure 1: Manhattan plot of the meta-GWAS discovery phase 392 
Circular plot of p-values from a inverse variance weighted fixed-effect meta-analysis of 393 
association of 16,531,985 genetic markers to allergic rhinitis from the discovery phase, including 394 
212,120 individuals. Only markers with p < 1e-3 are shown. Labels indicate nearest gene name 395 
for index marker in locus (marker with lowest p-value). Green labels indicate loci previously 396 
associated with allergy; blue labels indicate novel AR loci; grey labels indicate novel loci that 397 
were not carried forward to the replication phase. Green line indicates level of genome wide 398 
significance (p = 5e-8).   399 
 400 
Figure 2: Structural visualization of amino acid variants associated with allergic rhinitis  401 
The surface of the MHC molecule is shown in white, while the backbone of the bound peptide is 402 
shown in dark gray. The amino acid variant in focus is highlighted in red and the peptide binding 403 
pockets of the MHC molecule is indicated with dashed circles and annotated P1-P9. (A) The 404 
amino acid variant with strongest association to AR is HLA-DQB1 His30 (MHC class II), located 405 
close to P6 with a distance of 6Å to the peptide (excluding the peptide side chain). The 406 
protective amino acid variant at this location in relation to AR is hisitidine, whereas the risk 407 
variant is serine. Histidine is positively charged and has a large aromatic ring, whereas serine is 408 
not charged and not aromatic. Therefore, this mutation results in a significant change of the 409 
binding pocket environment. (B) The strongest AR-associated amino acid variation in HLA-B 410 
(MHC class I) is HLA-B AspHisLeu116, located close to P9 with a distance of 7Å to the peptide 411 
(excluding the peptide side chain). The close proximity to the bound peptide for both variants 412 
indicates that they are likely to affect the MHC-peptide interaction and thereby which peptides 413 
are presented. 414 
 415 
Figure 3: Enrichment of allergic rhinitis-associated variants in tissue-specific open 416 
chromatin 417 
Enrichment of 16,531,985 genetic variants associated with allergic rhinitis in 212,120 individuals 418 
(at p < 1e-08 as threshold for marker association) in 189 cell types from ENCODE and 419 
Roadmap epigenomics data. Enrichment and p-value was calculated empirically against a 420 
permuted genomic background using the GARFIELD tool. Red labels indicate blood and blood-421 
related cell-types, grey labels indicate other cell types. Due to number of permutations = 1e7, 422 
empirical p-values reached a minimum ceiling of 1/1e7. FDR threshold = 0.00026. For epstein-423 
Barr virus transformed B-lymphocyte cell types (cell type “GM****”), only most enriched instance 424 
is shown (“B-Lymphocyte”). NHEK = normal human epidermal keratinocytes, HMEC/vHMEC = 425 
mammary epithelial cells, HCM = human cardiac myocytes , WI-38 = lung fibroblast-derived, 426 
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HRGEC = human renal glomerular endothelial cell, HCFaa = Human Cardiac Fibroblasts-Adult 427 
Atrial cell, HMVEC−dBl−Neo = human microvascular endothelial cells, Th1 = T helper cell, type 428 
1, Th2 = T helper cell, type 2. 429 
 430 
Figure 4: Interaction network between drugs and proteins from genes associated with 431 
allergic rhinitis 432 
Grey nodes represent locus genes as well as genes prioritized from e/meQTL and PCHiC 433 
sources, based on genetics association of 16,531,985 markers with allergic rhinitis in 212,120 434 
individuals. Blue nodes represent drugs from the ChEMBL drug database. Edges represent 435 
very-high confidence interactions from the STRING database (for locus-locus interactions) and 436 
drug target evidence (for drug-locus interactions). Red borders indicate genes with protein 437 
products that were significantly enriched in the “Th1 and Th2 Activation” pathway (-log[p-value] 438 
>19.1) from the IPA pathway analysis. 439 
  440 
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Table 1. Association results of index markers (variant with lowest p-value for each locus) previously reported in 441 
relation to AR or other inhalant allergy. Column “Nearest gene” denotes nearest up- and downstream gene (for 442 
intergenic variants with two genes listed), or surrounding gene (for intronic variants with one gene listed), with the 443 
exception of rs5743618, an exonic missense variant within TLR1. EA/OA=effect allele/other allele. P-value is 444 
calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test.  445 
 446 
    Discovery 
Variant Locus Nearest genes EA/OA EAF n (studies) OR 
 
95% conf.int P Het. P 
Known          
rs34004019 6p21.32 HLA-DQB1;HLA-DQA1 G/A 0.27 196,951 (11) 0.89 0.87-0.90 1.00E-30 0.41 
rs950881 2q12.1 IL1RL1;IL1RL1 T/G 0.15 212,120 (18) 0.88 0.87-0.90 1.74E-30 0.91 
rs5743618 4p14 TLR1;TLR10 A/C 0.27 210,652 (17) 0.90 0.89-0.92 4.38E-27 0.70 
rs1438673 5q22.1 CAMK4;WDR36 C/T 0.50 212,120 (18) 1.08 1.07-1.10 3.15E-26 0.26 
rs7936323 11q13.5 LRRC32;C11orf30 A/G 0.48 212,120 (18) 1.08 1.06-1.09 6.53E-24 0.0001 
rs2428494 6p21.33 HLA-B;HLA-C A/T 0.42 195,753 (12) 1.08 1.06-1.09 7.01E-19 0.25 
rs11644510 16p13.13 RMI2;CLEC16A T/C 0.37 212,120 (18) 0.93 0.92-0.95 1.58E-17 0.65 
rs12939457 17q12 GSDMB;ZPBP2 C/T 0.44 212,120 (18) 0.94 0.92-0.95 2.35E-17 0.02 
rs148505069 4q27 IL21;IL2 G/A 0.33 212,120 (18) 1.07 1.05-1.08 2.54E-15 0.02 
rs13395467 2p25.1 ID2;RNF144A G/A 0.28 212,120 (18) 0.94 0.92-0.95 9.93E-15 0.61 
rs9775039 9p24.1 IL33;RANBP6 A/G 0.16 212,120 (18) 1.08 1.06-1.10 2.22E-14 0.40 
rs2164068 2q33.1 PLCL1 A/T 0.49 212,120 (18) 0.94 0.93-0.96 4.21E-14 0.82 
rs2030519 3q28 TPRG1;LPP G/A 0.49 212,120 (18) 1.06 1.04-1.07 1.83E-13 0.12 
rs11256017 10p14 CELF2;GATA3 T/C 0.18 212,120 (18) 1.07 1.05-1.09 2.72E-12 0.60 
rs17294280 15q22.33 AAGAB;SMAD3 G/A 0.25 212,120 (18) 1.07 1.05-1.09 5.97E-12 0.07 
rs7824993 8q21.13 ZBTB10;TPD52 A/G 0.37 212,120 (18) 1.05 1.04-1.07 1.86E-10 0.56 
rs9282864 16p11.2 SULT1A1;SULT1A2 C/A 0.33 208,761 (16) 0.94 0.93-0.96 4.69E-10 0.03 
rs9687749 5q31.1 IL13;RAD50 T/G 0.44 207,604 (16) 1.06 1.04-1.09 1.84E-09 0.19 
rs61977073 14q21.1 TTC6 G/A 0.22 212,120 (18) 1.06 1.04-1.08 5.78E-09 0.05 
rs6470578 8q24.21 TMEM75;MYC T/A 0.28 212,120 (18) 1.05 1.03-1.07 4.36E-08 0.02 
rs3787184 20q13.2 NFATC2;KCNG1 G/A 0.19 207,604 (16) 0.94 0.93-0.96 4.76E-08 0.69 
 447 
  448 
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Table 2. Association results of index markers (variant with lowest p-value for each locus) not previously associated with AR reaching a Bonferroni-corrected significance 9 
threshold of 0.05 in the replication phase. Column “Nearest gene” denotes nearest up- and downstream gene (for intergenic variants with two genes listed), or surrounding 0 
gene (for intronic variants with one gene listed), with the exception of rs1504215, an exonic synonymous variant within BACH2. EA/OA=effect allele/other allele. P-value is  
calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test. * Variants also reported associated with a combined 2 
asthma/eczema/hay fever phenotype by Ferreira et al.29 (within +/- 1Mb). 3 
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    Discovery Replication Combined 
Variant Locus Nearest genes EA/ OA EAF n (studies) OR 
95% 
conf.int P 
Het. 
P n (studies) OR 
95% 
conf.int P FWER n (studies) OR 
95% 
conf.int P 
Het. 
P 
rs7717955* 5p13.2 CAPSL; IL7R T/C 0.27 212,120 (18) 0.95 0.93-0.96 1.50E-09 0.24 679,247 (10) 0.93 0.91-0.94 4.09E-25 1.06E-23 891,367 (28) 0.94 0.93-0.95 3.78E-32 0.09 
rs63406760* 12q24.31 CDK2AP1; C12orf65 G/- 0.26 210,652 (17) 0.93 0.91-0.95 5.12E-14 0.91 675,338 (7) 0.95 0.93-0.96 3.27E-12 8.51E-11 885,990 (24) 0.94 0.93-0.95 2.54E-24 0.89 
rs1504215* 6q15 BACH2; GJA10 A/G 0.34 207,604 (16) 0.95 0.94-0.97 1.49E-08 0.02 679,247 (10) 0.95 0.94-0.97 1.99E-11 5.17E-10 886,851 (26) 0.95 0.94-0.96 1.54E-18 0.05 
rs28361986* 11q23.3 CXCR5; DDX6 A/T 0.20 212,120 (18) 0.93 0.91-0.95 1.81E-14 0.87 675,919 (8) 0.94 0.93-0.96 7.92E-11 2.06E-09 888,039 (26) 0.94 0.92-0.95 2.32E-23 0.91 
rs2070902* 1q23.3 AL590714.1; FCER1G T/C 0.25 212,120 (18) 1.06 1.04-1.08 1.03E-10 0.18 679,247 (10) 1.05 1.03-1.06 7.27E-10 1.89E-08 891,367 (28) 1.05 1.04-1.06 6.19E-19 0.23 
rs111371454* 15q15.1 ITPKA; RTF1 G/A 0.21 212,120 (18) 1.06 1.03-1.08 1.65E-07 0.17 675,338 (7) 1.04 1.03-1.06 8.47E-09 2.20E-07 887,458 (25) 1.05 1.03-1.06 1.28E-14 0.22 
rs12509403* 4q24 MANBA; NFKB1 T/C 0.32 212,120 (18) 0.95 0.94-0.97 9.97E-09 0.27 679,247 (10) 0.96 0.95-0.97 1.86E-08 4.84E-07 891,367 (28) 0.96 0.95-0.97 1.17E-15 0.39 
rs9648346* 7p15.1 JAZF1; TAX1BP1 G/C 0.22 207,604 (16) 1.05 1.03-1.07 3.62E-08 0.74 679,247 (10) 1.04 1.03-1.06 1.39E-07 3.63E-06 886,851 (26) 1.05 1.03-1.06 3.30E-14 0.48 
rs35350651* 12q24.12 ATXN2; SH2B3 C/- 0.49 206,136 (15) 1.04 1.03-1.06 6.63E-08 0.60 672,701 (6) 1.04 1.02-1.05 1.41E-07 3.66E-06 878,837 (21) 1.04 1.03-1.05 5.82E-14 0.43 
rs2519093* 9q34.2 ABO; OBP2B T/C 0.20 212,120 (18) 1.06 1.04-1.09 4.96E-11 0.38 675,919 (8) 1.04 1.03-1.06 2.96E-07 7.68E-06 888,039 (26) 1.05 1.04-1.07 2.79E-16 0.61 
rs62257549 3p21.2 VPRBP A/G 0.20 212,120 (18) 0.95 0.93-0.97 7.13E-08 0.45 677,615 (9) 0.96 0.94-0.97 3.37E-07 8.76E-06 889,735 (27) 0.95 0.94-0.97 1.84E-13 0.53 
rs11677002 2p23.2 FOSL2; RBKS C/T 0.45 212,120 (18) 0.96 0.95-0.98 3.80E-07 0.21 679,247 (10) 0.97 0.96-0.98 3.54E-07 9.20E-06 891,367 (28) 0.97 0.96-0.97 7.08E-13 0.36 
rs35597970* 10q24.32 ACTR1A; TMEM180 -/A 0.45 210,652 (17) 1.06 1.04-1.07 1.34E-13 0.96 676,970 (8) 1.03 1.02-1.05 4.37E-07 1.14E-05 887,622 (25) 1.04 1.03-1.05 5.42E-18 0.53 
rs2815765 1p31.1 LRRIQ3; NEGR1 T/C 0.37 212,120 (18) 0.95 0.94-0.97 1.18E-09 0.59 679,247 (10) 0.97 0.95-0.98 6.16E-07 1.60E-05 891,367 (28) 0.96 0.95-0.97 9.45E-15 0.52 
rs11671925* 19q13.11 CEBPA; SLC7A10 A/G 0.17 206,136 (15) 0.94 0.92-0.96 1.80E-08 0.97 677,551 (9) 0.96 0.94-0.98 2.80E-06 7.29E-05 883,687 (24) 0.95 0.94-0.96 5.91E-13 0.60 
rs2461475* 12q24.31 SPPL3; ACADS C/T 0.47 212,120 (18) 1.04 1.02-1.05 9.19E-07 0.97 677,551 (9) 1.03 1.02-1.04 6.52E-06 0.0002 889,671 (27) 1.03 1.02-1.04 3.81E-11 0.83 
rs6738964* 2q36.3 SPHKAP; DAW1 G/T 0.24 212,120 (18) 0.96 0.94-0.97 4.51E-07 0.72 679,247 (10) 0.97 0.96-0.98 4.96E-05 0.0013 891,367 (28) 0.96 0.95-0.97 1.86E-10 0.87 
rs10519067* 15q22.2 RORA A/- 0.13 212,120 (18) 0.93 0.91-0.96 1.78E-09 0.37 442,354 (7) 0.93 0.90-0.96 7.53E-05 0.0020 654,474 (25) 0.93 0.92-0.95 5.53E-13 0.36 
rs138050288* 1p36.23 RERE; SLC45A1 -/CA 0.29 210,652 (17) 1.05 1.04-1.07 5.96E-10 0.71 675,338 (7) 1.03 1.01-1.04 0.0002 0.0046 885,990 (24) 1.04 1.03-1.05 6.62E-12 0.63 
rs7328203 13q14.11 TNFSF11; AKAP11 G/T 0.46 212,120 (18) 1.05 1.03-1.06 5.94E-09 0.90 677,551 (9) 1.02 1.01-1.04 0.0005 0.0134 889,671 (27) 1.03 1.02-1.04 1.28E-10 0.78 
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Methods: 456 
Phenotype definition  457 
Allergic rhinitis (AR) 458 
Cases were defined as individuals ever having a diagnosis or symptoms of AR dependent on 459 
available phenotype definitions in the included studies (Supplementary Table 3 and cohort 460 
recruitment details in Supplementary Note). All relevant ethical regulations were followed as 461 
specified in relation to the individual studies in the Supplementary Note. To maximize numbers 462 
and optimize statistical power, we did not require doctor-diagnosed AR or verification by allergic 463 
sensitization. This approach was confirmed by a sensitivity analysis in 23andMe based on 464 
association with known risk loci for allergic rhinitis (data not shown). Controls were defined as 465 
individuals who never had a diagnosis or symptoms of AR.  466 
 467 
Allergic sensitization (AS) 468 
We considered specific IgE production against inhalant allergens without restriction by 469 
assessment method or type of inhalant allergen. Cases were defined as individuals with 470 
objectively measured sensitization against at least one of the inhalant allergens tested for in the 471 
respective studies, and controls were defined as individuals who were not sensitized against 472 
any of the allergens tested for. We included sensitization assessed by skin reaction after 473 
puncture of the skin with a droplet of allergen extract (SPT) and/or by detection of the levels of 474 
circulating allergen-specific IgE in the blood. The SPT wheal diameter cutoffs were 3 mm larger 475 
than the negative control for cases and smaller than 1 mm for controls. To optimize case 476 
specificity and the correlation between methods, we chose a high cutoff of specific IgE levels for 477 
cases (0.7 IU/ml) and a low cutoff for controls (0.35 IU/ml).  478 
 479 
Non-allergic rhinitis (NAR) 480 
Case were defined as individuals with current allergic rhinitis symptoms (within the last 12 481 
months) and no allergic sensitization (negative specific IgE (< 0.35 IU/mL) and/or negative skin 482 
prick test (< 1 mm) for all allergens and time points tested) 483 
Controls were defined as individuals never having symptoms of allergic rhinitis and no allergic 484 
sensitization (negative specific IgE (< 0.35 IU/mL) and/or negative skin prick test (< 1 mm) for all 485 
allergens and time points tested) 486 
 487 
For all 3 phenotypes, we combined data from children and adults but chose a lower age limit of 488 
6 years, as allergic rhinitis and sensitization status at younger ages show poorer correlation with 489 
status later in life, both owing to transient symptoms/sensitization status and frequent 490 
development of symptoms/sensitization during late childhood. 491 
GWAS QC and cohort summary data harmonization 492 
For AR, AS, and NAR, each cohort imputed their data separately using the 1000 Genomes 493 
Project (1KGP) phase 1, version 3 release, and conducted the genome-wide association 494 
 2 
analysis adjusted for sex and if necessary for age and principal components (Supplementary 495 
Table 3). All studies included individuals of European descent, except Generation R and 496 
RAINE, comprising a mixed, multi-ethnic population. We utilized EasyQC v. 9.236 for quality 497 
control and marker harmonization for cohort-level meta-GWAS summary files. Cohort data was 498 
harmonized to genome build GRCh37 and checked against 1KGP phase 3 reference allele 499 
frequencies for processing problems. GWAS summary “karyograms” were visually inspected to 500 
catch cohorts with incomplete data. Distributions of estimate coefficients and errors, as well as 501 
“Standard error vs. sample size”- and “p value vs. z-score” plots were inspected for each cohort 502 
for systematic errors in statistical models. Ambiguous markers that were non-unique in terms of 503 
both genomic position and allele coding were removed. A minimum imputation score of 0.3 (R2) 504 
or 0.4 (proper_info) was required for markers. A minimum minor allele count of 7 was required 505 
for each marker in each cohort, as suggested by the GIANT consortium and EasyQC. 506 
 507 
Meta-Analysis 508 
For AR, AS, and NAR, meta-analysis for the discovery phase was conducted using GWAMA37 509 
with an inverse variance weighted fixed-effect model with genomic control correction of the 510 
individual studies. Each locus is represented by the variant showing the strongest evidence 511 
within a 1Mb buffer. Loci were inspected visually by plotting genomic neighbourhood and 512 
coloring for 1KGP r2 values. From the pool of genomewide significant markers in the discovery, 513 
one locus with index marker rs193243426 without a credible LD structure was removed from 514 
further analysis (Supplementary Fig. 10). Heterogeneity was assessed with Cochran’s Q test. 515 
Meta-analysis of replication candidates from the AR discovery phase was carried out using R 516 
version 3.4.0, and the meta package version 4.8-2 with an inverse variance weighted fixed-517 
effect model. For a subset of markers, cohorts reported suitable proxies (r2>0.85), where 518 
followed-up markers were not present or had insufficient imputation or genotyping quality 519 
(Supplementary Table 25).  520 
Gene set overrepresentation analysis, discovery phase 521 
To facilitate selection of biologically relevant discovery candidates in the sub-genomewide 522 
significant stratum (5e-8 < p < 1e-6), we employed a custom gene set overrepresentation 523 
analysis algorithm implemented in R, with a scoring and permutation regime modeled after 524 
MAGENTA.38 Genes with lengths less than 200bp, with copies on multiple chromosomes, and 525 
with multiple copies on the same chromosome more than 1Mb apart were removed from 526 
analysis. Gene models (GENCODE v 19) were downloaded from the UCSC Table Browser,39 527 
and expanded 110 kb upstream, and 40 kb downstream, similar to MAGENTA. The HLA region 528 
was excluded from analysis (chromosome 6: 29,691,116-33,054,976). Similar to MAGENTA, 529 
gene scores were adjusted for number of markers per gene, gene width, recombination 530 
hotspots, genetic distance, and number of independent markers per gene, all with updated data 531 
from UCSC Table Browser. For the gene set overrepresentation permutation calculation, gene 532 
sets from the MSigDB collections c2, c3, c5, c7, and hallmark, were included.40 A MAGENTA-533 
style enrichment cutoff at 95% was used. Gene sets with FDR<0.05 were considered. 534 
 3 
Conditional analyses 535 
To identify additional independent markers at each discovery genomic region, we used 536 
Genome-wide Complex Trait Analysis (GCTA) v. 1.26.0.41 Within a window of +/- 1Mb of each 537 
discovery phase index marker, all markers were conditioned on the index using the --cojo-cond 538 
feature of GCTA with default parameters. Plink v. 1.90b3.4242 was used to calculate r2 for GCTA 539 
with the UK10K full genotype panel43 as reference. A total of 42 of 52 markers from the full 540 
discovery phase were present in UK10K. As a MAF-dependent inflation of conditional p-values 541 
was observed (data not shown), only conditional markers with MAF >= 10% were selected. 542 
Locus definition and credible sets for VEP annotation 543 
Discovery loci were defined as index markers extended with markers in LD (r2 >= 0.5), based on 544 
the 1KGP phase 3. Protein coding gene transcript models (GENCODE v. 24) were downloaded 545 
from the UCSC Table Browser, and nearest upstream, downstream, as well as all genes within 546 
the extended loci were annotated. 547 
Credible sets for each locus were calculated using the method of Morris, A.P44. 548 
LD was calculated for each discovery index variant within +/- 500 kb, and markers with r2<0.1 549 
were excluded. For the remaining markers, the Bayesian Factor (ABF) values and the posterior 550 
probabilities (PostProb) were calculated, and cumulative posterior probability values were 551 
generated based ranking markers on ABF. Finally, variants were included in the 99% credible 552 
set until the cumulative posterior probability was greater or equal than 0.99. 553 
Credible sets for each loci was annotated with information on mutation impact in coding regions 554 
using the Variant effect Prediction (VeP) REST API45, exporting only the nonsynonymous 555 
substitutions. 556 
GWAS catalogue lookup 557 
For annotation of markers with identification in previous GWA studies, the GWAS catalog was 558 
downloaded from NHGRI-EBI (v.1.0.1, 2016-11-28). For this analysis, AR loci were lifted from 559 
genomic build GRCh37 to GRCh38, and extended with +/- 1Mb in each direction before being 560 
overlapped with GWAS catalog annotations. Relevant GWAS catalog overlap traits were binned 561 
into trait groups “Allergic Rhinitis”, “Asthma”, “Autoimmune”, “Eczema”, “Infectious Diseases”, 562 
“Lung-related Traits”, and “Other allergy”. A million random genomic intervals of the same length 563 
(2Mb) were obtained to generate a background overlap distribution, and p-values were 564 
calculated from this background. 565 
HLA classical allele analysis 566 
Analyses of imputed classical HLA-alleles were performed in the 23andMe study (AR discovery 567 
population) comprising 49,180 individuals with allergic rhinitis and 124,102 controls.  568 
HLA imputation was performed with HIBAG v. 1.2.3.46 We imputed allelic dosage for HLA-A, B, 569 
C, DPB1, DQA1, QB1, and DRB1 loci at four-digit resolution using the default settings of HIBAG 570 
for a total of 292 classical HLA alleles.  571 
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Using an approach suggested by P. de Bakker,47 we downloaded the files that map HLA alleles 572 
to amino acid sequences from https://www.broadinstitute.org/mpg/snp2hla/ and mapped our 573 
imputed HLA alleles at four-digit resolution to the corresponding amino acid sequences; in this 574 
way we translated the imputed HLA allelic dosages directly to amino acid dosages. We encoded 575 
all amino acid variants in the 23andMe European samples as 2395 bi-allelic amino acid 576 
polymorphisms as previously described.48  577 
Similar to the SNP imputation, we measured imputation quality using r2, which is the ratio of the 578 
empirically observed variance of the allele dosage to the expected variance assuming Hardy-579 
Weinberg equilibrium.  580 
To test associations between imputed HLA alleles, amino acid variants, and phenotypes, we 581 
performed logistic regression using the same set of covariates used in the SNPbased GWAS. 582 
We applied a forward stepwise strategy, within each type of variant, to establish statistically 583 
independent signals in the HLA region. Within each variant type, we first identified the most 584 
strongly associated signals (lowest p-value) and performed forward iterative conditional 585 
regression to identify other independent signals. All analyses were controlled for sex and five 586 
principal components of genetic ancestry. The p-values were calculated using a likelihood ratio 587 
test.  588 
 589 
Structural visualization of amino acid variants 590 
Structural visualization of amino acid variants was performed for the strongest associated 591 
variants in HLA-DQB1 (position 30) and HLA-B (position 116), respectively (Supplementary 592 
Table 10) and were made using X-ray structures from the Protein Data Bank (PDB).49 To find 593 
the best structure we used the specialized search function in the Immune Epitope Database,50 594 
selecting only X-ray crystalized structures for the specific MHC classes HLA-DQB1 (class II) 595 
and HLA-B (class I). Using this criterion, we found 17 crystallized structures for HLA-DQB1 and 596 
164 structures for HLA-B. From these lists, we selected the structure with the lowest resolution 597 
and the amino acids encoded by the reported top SNPs. The PDB accession code for the 598 
selected structures was 4MAY51 for HLA-DQB1 and 2A8352 for HLA-B and both structures were 599 
visualized using PyMOL v. 1.8.2.1 (http://www.pymol.org). Furthermore, we used PyMOL to 600 
measure intra-molecular distances from the side chain of the amino acids associated with 601 
allergic rhinitis to the C atoms in the peptide. This distance measure was chosen to 602 
accommodate the possibility for different amino acids in the peptide. In order for two amino 603 
acids to interact the distance should be approximately 4Å or less. We measured distances of 6Å 604 
(HLA-DQB1) and 7Å (HLA-B). However these distances do not include the peptide side chains 605 
which range from 1.5 Å – 8.8 Å. Therefore, we estimate that physical interaction between the 606 
amino acids encoded by the top SNPs and the peptide is likely. 607 
Genetic heritability and genetic correlation 608 
For calculating genetic heritability and genetic correlation between AR and AS, as well as 609 
between clinical cohorts and 23andMe within AR, we utilized the LD score regression based 610 
method as implemented by LDSC v. 1.0.45,53 Population prevalence was set to 10% for AR and 611 
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AS. Genetic correlation analysis between AR, AS and published GWAS studies was carried out 612 
using the LDHUB platform v. 1.3.154 against all traits, but excluding Metabolites55.    613 
eQTL sources and analysis 614 
From GTEx V6p56, all significant variant-gene cis eQTL pairs for whole blood, lung, and EBV-615 
transformed lymphocytes were downloaded from https://gtexportal.org, and carried forward in 616 
analysis. From Westra et al.57, both cis and trans eQTLs in whole blood were downloaded, and 617 
variant-gene pairs with FDR < 0.1 were carried forward in analysis. From Fairfax et al.58, cis 618 
eQTLs from monocytes and B cells were downloaded, and variant-gene pairs with FDR < 0.1 619 
were carried forward in analyses. From Bonder et al.58, meQTLs from whole blood were 620 
downloaded, and variant-probe pairs with FDR < 0.05 were carried forward in analyses. From 621 
Nicodemus-Johnson et al.59, cis eQTLs and meQTLs from lung were downloaded, and variant-622 
gene pairs with FDR < 0.1 were carried forward in analyses. From Momozawa et al. [in press, 623 
personal correspondence], cis eQTLs from blood cell types CD14, CD15, CD19, CD4, and CD8 624 
were downloaded, and variant-gene pairs with a weighted correlation of >= 0.6 were carried 625 
forward to analysis. For supplementary table 14 priority genes, protein coding information was 626 
downloaded from the UCSC Table Browser, using the “transcriptClass” field from the 627 
“wgEncodeGencodeAttrsV24lift37” table. 628 
Promoter Capture Hi-C Gene Prioritisation 629 
To assess spatial promoter interactions in the discovery set, we performed a Capture Hi-C 630 
Gene Prioritisation (CHIGP) as described in Javierre et al.60 and 631 
https://github.com/ollyburren/CHIGP using recommended settings and data sources: 0.1cM 632 
recombination blocks, 1KGP EUR reference population, coding markers from the GRCh37 633 
Ensembl assembly and the CHICAGO-generated61 Promoter Capture Hi-C peak matrix data 634 
from 17 human primary blood cell types supplied in the original paper. The resulting protein-635 
coding prioritized genes (gene score > 0.5) were used in the downstream network analysis, 636 
from cell types "Fetal thymus", "Total CD4 T cells", "Activated total CD4 T cells", "Non-activated 637 
total CD4 T cells", "Naive CD4 T cells", "Total CD8 T cells", "Naive CD8 T cells", "Total B cells", 638 
"Naive B cells", "Endothelial precursors", "Macrophages M0", "Macrophages M1", 639 
"Macrophages M2", "Monocytes", and "Neutrophils". 640 
Gene set overrepresentation analysis of known and replicating novel loci 641 
All high-confidence gene symbols from eQTL and meQTL sources, PCHiC, as well as genes 642 
(models extended 110kb upstream, and 40kb downstream) within each r2-based loci definition  643 
from known and replicating novel loci were input into the pathway-based set over-representation 644 
analysis module of ConsensusPathDB (CPDB) database and tools62 with 229 of 277 gene 645 
identifiers translated. In addition, these same symbols were used for Ingenuity pathway analysis 646 
(IPA; www.ingenuity.com; a curated database of the relationships between genes obtained from 647 
published articles, and genetic and expression data repositories) to identify biological pathways 648 
common to genes. IPA determines whether the associated genes are significantly enriched in a 649 
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specific biological function or network by assessing direct interactions. We assigned significance 650 
if right-tailed Fisher’s exact test p-value < 0.05. 651 
eQTL/meQTL, PCHiC and locus gene intersections were visualized using the UpSetR package 652 
(v1.3.2) 63. 653 
Tissue overrepresentation 654 
To assay the enrichment of variants associated with AR in tissue specific gene expression sets, 655 
we utilized the DEPICT enrichment method64, using a p-value threshold of 1e-5, and standard 656 
settings.    657 
Enrichment of regulatory regions 658 
To assay the enrichment of variants associated with AR in regions of open chromatin and 659 
specific histone marks, we utilized the GWAS Analysis of Regulatory or Functional Information 660 
Enrichment with LD correction (GARFIELD v. 1) method65. In essence, GARFIELD performs 661 
greedy pruning of GWAS markers (LD r2 > 0.1) and then annotates them based on functional 662 
information overlap. Next, it quantifies Fold Enrichment (FE) at various GWAS significance 663 
cutoffs and assesses them by permutation testing, while adjusting for minor allele frequency, 664 
distance to nearest transcription start site and number of LD proxies (r2 > 0.8). GARFIELD was 665 
run with 10,000,000 permutations, and otherwise default settings. 666 
PARF 667 
Population-attributable risk fractions (PARFs) were estimated from B58C, a general-population 668 
sample with participant ages 44-45 years also contributing to the discovery stage. The genetic 669 
risk score was calculated by applying the pooled per-allele coefficients (ln(OR) values) from the 670 
AR discovery set to the number of higher-risk alleles of each of the 41 established (known 671 
genome-wide significant and novel replicated loci), one SNP per locus. Because there were no 672 
individuals observed with zero higher-risk alleles, the prevalence of sensitization for individuals 673 
in the lowest decile of the genetic risk score distribution was used to derive PARF estimates on 674 
the assumption that this 10% of the population was unexposed. This method has the advantage 675 
that it does not predict beyond the bounds of the data, but its results are conservative. The 676 
PARF was then derived (with 95% confidence interval) by expressing the difference between 677 
the observed prevalence and the predicted (unexposed) prevalence as a percentage of the 678 
observed prevalence. PARFs were estimated using the 41 AR loci in relation to AR, AS and 679 
NAR, respectively. 680 
Protein network and drug interactions 681 
In order to analyse protein-protein-drug interaction networks, STRING (V10)66 was used. Protein 682 
network data (9606.protein.links.v10.txt.gz) and protein alias data (9606.protein.aliases.v10.txt) 683 
files were downloaded from the string db website [http://string-db.org/]. GWAS hits stratified on 684 
‘all’, ‘blood’ and ‘lung’ were converted to Ensembl protein ids using the protein alias data. The 685 
interactors were subsequently identified using the link data at a ‘high confidence cutoff of >0.7’ 686 
 7 
as described in the STRING FAQ. The interactor Ensembl protein ids were then converted to 687 
UniProt gene names and both hits and interactors were then analyzed for interactions with FDA 688 
approved drugs using the ChEMBL Database v. 2267 API via Python (v. 2.7.12). Lastly, stratified 689 
networks consisting of GWAS hits connected to interactors and drugs connected to both GWAS 690 
hits and interactors were visualised using GGraph (v. 1.0.0), iGraph (v. 1.0.1), TidyVerse (v. 691 
1.1.1) under R (v. 3.3.2). 692 
Data availability 693 
Genome-wide results, excluding 23andMe, are available on request through the corresponding 694 
author. The full GWAS summary statistics for the 23andMe discovery data set will be made 695 
available through 23andMe to qualified researchers under an agreement with 23andMe that 696 
protects the privacy of the 23andMe participants. Please contact David Hinds 697 
(dhinds@23andme.com) for more information and to apply to access the 23andMe data. A Life 698 
Sciences Reporting Summary is available for this paper. 699 
 700 
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Introduction 107 
Allergic rhinitis is the most common clinical presentation of allergy, affecting 400 million people 108 
worldwide, and with increasing incidence in westernized countries.1,2 To elucidate the genetic 109 
architecture and understand disease mechanisms of allergic rhinitis, we carried out a meta-110 
analysis of allergic rhinitis in 59,762 cases and 152,358 controls of European ancestry and 111 
identified a total of 41 risk loci for allergic rhinitis, including 20 loci not previously associated with 112 
allergic rhinitis, which were confirmed in a replication phase of 60,720 cases and 618,527 113 
controls. Functional annotation implied genes involved in various immune pathways, and fine 114 
mapping of the HLA region suggested amino acid variants of importance for antigen binding. 115 
We further performed GWASs of allergic sensitization against inhalant allergens and non-116 
allergic rhinitis suggesting shared genetic mechanisms across rhinitis-related traits. Future 117 
studies of the identified loci and genes might identify novel targets for treatment and prevention 118 
of allergic rhinitis.   119 
 120 
Main text 121 
Allergic rhinitis (AR) is an inflammatory disorder of the nasal mucosa mediated by allergic 122 
hypersensitivity responses to environmental allergens1 with large adverse effects on quality of 123 
life and health care expenditures. The underlying causes for AR are still not understood and 124 
prevention of the disease is not possible. The heritability of AR is estimated to be more than 125 
65%3,4. Seven loci have been associated with allergic rhinitis in genome-wide association 126 
studies (GWAS) of AR per se, while other have been suggested from GWAS studies on related 127 
traits, such as self-reported allergy, asthma plus hay fever, or allergic sensitization5–9, but only 128 
few of these have been replicated. 129 
We carried out a large-scale meta-GWAS of AR including a discovery meta-analysis of 130 
16,531,985 genetic markers from 18 studies comprising 59,762 cases and 152,358 controls of 131 
primarily European ancestry (Supplementary Table 1, cohort recruitment details in 132 
Supplementary Note). We report the genetic heritability on the liability scale of AR as at least 133 
7.8% (assuming 10% disease prevalence), with a genomic inflation of 1.048 (Supplementary 134 
Figure 1). We identified 42 genetic loci, with index markers below genomewide significance 135 
(p<5e-8), of which 21 have previously been reported in relation to AR or other inhalant allergy6–9 136 
(Fig. 1, Table 1, Table 2, Supplementary Fig. 2, Supplementary Fig. 3).  137 
One study (23andMe) had a proportionally large weight (~80%) in the discovery phase. 138 
Overall there was good agreement between 23andMe and the other studies with respect to 139 
effect size and direction, and regional association patterns (Supplementary Table 2 and 140 
Supplementary Fig. 4+5), and the genetic correlation was 0.80 (p<2e-17). Heterogeneity 141 
between 23andMe and the remaining studies was statistically significant (p<0.05) for 7 of 42 142 
loci, in most cases due to a smaller effect size in 23andMe. This was likely due to many non-143 
23andMe studies using a more robust phenotype definition of doctor diagnosed AR 144 
(Supplementary Table 3), which tended to result in larger effect sizes (Supplementary Table 145 
4).  146 
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  The index markers from a total of 25 loci that had not previously been associated with 147 
AR or other inhalant allergy were carried forward to the replication phase. These included 16 148 
loci that showed genome-wide significant association in the discovery phase and evidence of 149 
association (p<0.05) in both 23andMe and non-23andMe studies (Supplementary Table 2), 150 
and an additional 9 loci that were selected from the p-value stratum between 5e-8 and 1e-6 151 
based on enrichment of gene sets involved in immune-signaling (Supplementary Table 5). 152 
Replication was sought in another 10 studies with 60,720 cases and 618,527 controls. Of the 25 153 
loci, 20 loci reached a Bonferroni-corrected significance threshold of 0.05 (p<0.0019) in a meta-154 
analysis of replication studies (Fig. 1 (blue), Table 2), and all of these reached genome-wide 155 
significance in the combined fixed-effect meta-analysis of discovery and replication studies 156 
(Table 2). Evidence of heterogeneity was seen for one of these loci (rs1504215), which did not 157 
reach statistical significance in the random effects model (0.95 [0.92; 0.97], p=2.83e-07, 158 
Supplementary Fig. 3).  159 
 A conditional analysis of top loci identified 13 additional independent variants at p<1e-5, 160 
with 4 of these being genome-wide significant (near WDR36, HLA-DQB1, IL1RL1 and LPP) 161 
(Supplementary Table 6 and Supplementary Fig. 5, bottom panel). 162 
To gain insight into functional consequences of known and novel loci, we utilized a 163 
number of data sources, including 1) 11 eQTL sets and 1 meQTL set from blood and blood 164 
subsets; 2) 2 eQTL sets and 1 meQTL set from lung tissue; and 3) data on enhancer-promoter 165 
interactions in 15 different blood subsets. Support of regulatory effects on coding genes was 166 
found for 33 out of the 41 loci. Many loci showed evidence of regulatory effects across a wide 167 
range of immune cell types (including B- and T-cells), while other seemed cell type-specific 168 
(Supplementary Table 7). Calculation of the “credible set” of markers for each locus using a 169 
Bayesian approach that selects markers likely to contain the causal disease-associated markers 170 
(Supplementary Table 8) and looking up these in the Variant Effect Predictor database 171 
generated a list of 17 markers producing amino acid changes, including deleterious changes in 172 
NUSAP1, SULT1A1 and PLCL, as predicted by SIFT (Supplementary Table 9). 173 
The major histocompatibility complex (MHC) on chr6p harbored some of the strongest 174 
association signals in the GWAS with independent signals located around HLA-DQB and HLA-175 
B, respectively. The top variant at HLA-DQB was an eQTL for several HLA-genes, including 176 
HLA-DQB1, HLA-DQA1, HLA-DQA2, and HLA-DRB1 in immune and/or lung tissue, and the top 177 
variant at HLA-B was an eQTL for MICA (Supplementary Table 7). In addition we found 178 
associations with several classical HLA alleles, including HLA-DQB1*02:02, HLA-DQB1*03:01, 179 
HLA-DRB1*04:01, and HLA-C*04:01, which were in weak LD (r2<0.1) with the GWAS top SNPs 180 
(Supplementary Tables 10 and 11), and strong associations with well imputed amino acid 181 
variants, including HLA-DQB1 His30 (p=2.06e-28, OR=0.91) and HLA-B AspHisLeu116 182 
(p=6.00e-13, OR=1.06) (Supplementary Tables 12 and 13). Within HLA-DQB1, the amino acid 183 
variant was in moderate LD (r2=0.71) with the GWAS top SNP and accounted for most of the 184 
SNP association (rs34004019, p=2.18e-28, OR=0.88, conditional p-value=1.35e-03). Within 185 
HLA-B, the strongest associated amino acid variant was only in weak LD (r2=0.23) with the top 186 
SNP and accounted for a small part of the SNP association (rs2428494, p=3.99e-15, OR=1.07, 187 
conditional p-value=3.23e-10 ). Importantly, the strongest associated amino acid variants in 188 
HLA-DQB1 and HLA-B, respectively were both located in the peptide binding pockets with a 189 
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high likelihood of affecting MHC-peptide interaction (Figure 2). MHC class II molecules, 190 
including HLA-DQ, are known for their role in allergen-binding and Th2 driven immune 191 
responses10 and our results therefore suggest that the GWAS signal at this locus involves 192 
structural changes related to allergen binding properties. This might be in addition to  gene 193 
regulatory effects similar to what has been found for autoimmune disease.11,12 194 
The majority of the 20 loci not previously associated with AR per se imply genes with a known 195 
role in the immune system, including IL7R13, 14, SH2B315, CEBPA/CEBPG16, 17, CXCR518, 196 
FCER1G, NFKB119, BACH220, 21, TYRO322, LTK 23, VPRBP24, SPPL325, OASL26, RORA27, and 197 
TNFSF1128. Other loci imply genes with no clear function in AR pathogenesis. These include 198 
one of the strongest associated loci in this meta-analysis at 12q24.31 with the top-signal located 199 
between CDK2AP1 and C12orf65, harboring cis-eQTLs in blood and lung tissue for several 200 
genes and evidence for enhancer-promoter interaction with DDX55 in various immune cells. 201 
(Supplementary Table 14 and further locus description in the Supplementary Note). 202 
Concomitantly with the current study, a GWAS combining asthma, eczema and AR was 203 
conducted.29 The majority (15/20) of identified AR loci in our study were also suggested in the 204 
previous, more unspecific, GWAS29 (as indicated in Table  2), while many suggested loci from 205 
the previous GWAS were not identified in our study. Asthma, eczema and allergic rhinitis are 206 
related but distinct disease entities, often with seperate disease mechanisms, e.g. allergic 207 
sensitization is present in only 50% of children with asthma30 and 35% of children with 208 
eczema.31 Our results therefore complement those from the less specific “atopic phenotype” 209 
GWAS29 by pinpointing loci specifically associated, and replicated, in relation to allergic rhinitis.   210 
AR loci were significantly enriched (p<1e-5) for variants reported to be associated with 211 
autoimmune disorders. Reported autoimmune variants were located within a 1mb distance of 31 212 
(76%) of the 41 AR loci. For 24 of these, an autoimmune top SNP was also associated with AR, 213 
and for 12 of these the autoimmune top SNP was in LD (r2>0.5) with the AR top SNP 214 
(Supplementary Table 15). For approximately half of these, the direction of effect was the 215 
same for the autoimmune and AR top SNP in line with a previous study,32 underlining the 216 
complex genetic relationship between AR and autoimmunity, which might involve shared as well 217 
as diverging molecular mechanisms.  218 
Assessment of enrichment of AR-associated variant burden in open chromatin as 219 
defined by DNAse hypersensitive sites showed a clear enrichment in several blood and immune 220 
cell subsets, with the largest enrichment in T-cells (CD3 expressing), B-cells (CD19 expressing), 221 
and T and NK-cells (CD56-expressing) (Fig. 3, Supplementary Table 16, Supplementary Fig. 222 
6). We also probed tissue enrichment by means of gene expression data from a wide number of 223 
sources, showing enrichment of AR genes in blood and immune cell subsets, as well as in 224 
tissues of the respiratory system, including oropharynx, respiratory and nasal mucosa 225 
(Supplementary Table 17).  226 
To explore biological connections and identify new pathways associated with AR, we 227 
combined all genes suggested from eQTL/meQTL analyses, enhancer-promoter interactions 228 
and localization within the top loci. The resultant prioritized gene set consisted of 255 genes, of 229 
which 89 (~36%) were present in more than one set (Supplementary Fig. 7). Overall, the full 230 
set was enriched for pathways involved in Th1 and Th2 Activation (Fig. 4), antigen presentation, 231 
cytokine signaling, and inflammatory responses (Supplementary Table 18).    232 
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Using the 255 prioritized genes in combination with STRING to identify proteins that 233 
interact with the proteins encoded by the high priority genes, we demonstrated a high degree of 234 
interaction at the protein level, and several of these proteins are target of approved drugs or 235 
drugs in development, including TNFSF11, NDUFAF1, PD-L1, IL-5, and IL-13  (Fig. 4).  236 
AR is strongly correlated to allergic sensitization (presence of allergen-specific IgE), but 237 
sensitization is often present without AR suggesting specific mechanisms determining 238 
progression from sensitization to disease. We therefore conducted a GWAS on sensitization to 239 
inhalant allergens (AS) comprising 8,040 cases and 16,441 controls from 13 studies 240 
(Supplementary Table 1), making it the largest GWAS on allergic sensitization to date7. A total 241 
of 10 loci reached genome-wide significance, including one novel hit near the FASLG gene 242 
(Supplementary Table 19). The genetic heritability on the liability scale was 17.75% (10% 243 
prevalence), considerably higher than the heritability of AR in consistency with a more 244 
homogeneous phenotype. Look-up of AR top-loci in the AS GWAS demonstrated large 245 
agreement with 40 of the 41 AR markers showing same direction of effect and 28 also showing 246 
nominal significance for AS (Supplementary Table 20). This suggests that AR and AS share 247 
biological mechanisms and that AS loci generally affect systemic allergic sensitization. We 248 
compared genetic pathways of AR and AS using the DEPICT tool showing overlap in enriched 249 
pathways but also differences among the top gene sets, with AR gene sets characterized by B-250 
cell, Th2, and parasite responses and AS gene sets characterized by a broader activation of 251 
cells (Supplementary Fig 8 and Supplementary Tables 21 and 22).  252 
Non-allergic rhinitis, defined as rhinitis symptoms without evidence of allergic 253 
sensitization, is a common but poorly understood disease entity.33 We performed the first 254 
GWAS on this phenotype hypothesizing that this might reveal specific rhinitis mechanisms. The 255 
analysis included 2,028 cases and 9,606 controls from 9 studies but did not identify any risk loci 256 
at the genome-wide significance level. Comparison with AR results suggested some overlap in 257 
susceptibility loci (Supplementary Note and Supplementary Table 23).  258 
We estimated the proportion of AR in the general population that can be attributed to the 259 
41 identified AR loci and obtained a conservative population-attributable risk fraction estimate of 260 
39% (95% CI 26%-50%), considering the 10% of the population with the lowest genetic risk 261 
scores to represent an ‘unexposed’ group. Allergic rhinitis prevalence plotted by genetic risk 262 
score (Supplementary Fig. 9) showed approximately 2 times higher prevalence in the 7% of 263 
the population with the highest risk score compared to the 7% with the lowest risk score.   264 
Finally, we investigated the genetic correlation of AR with AS, asthma34, and eczema35 265 
by LD score regression. There was a strong correlation between AR and AS (r2=0.73, p<2e-34), 266 
moderate with asthma (r2=0.60, p<3e-14) and weaker with eczema (r2=0.40, p<2e-07). 267 
The identified AR loci were tested for association with AR in non-European cohorts, only 268 
showing nominal significant association for a loci, but this analysis had limited statistical power 269 
due to population sizes (Supplementary Table 24).   270 
In conclusion, we expanded the number of established susceptibility loci for AR and 271 
highlighted involvement of AR susceptibility loci in diverse immune cell types and both innate 272 
and adaptive IgE-related mechanisms. Future studies of novel AR loci might identify targets for 273 
treatment and prevention of disease. 274 
 275 
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 390 
Figure legends 391 
Figure 1: Manhattan plot of the meta-GWAS discovery phase 392 
Circular plot of p-values from a inverse variance weighted fixed-effect meta-analysis of 393 
association of 16,531,985 genetic markers to allergic rhinitis from the discovery phase, including 394 
212,120 individuals. Only markers with p < 1e-3 are shown. Labels indicate nearest gene name 395 
for index marker in locus (marker with lowest p-value). Green labels indicate loci previously 396 
associated with allergy; blue labels indicate novel AR loci; grey labels indicate novel loci that 397 
were not carried forward to the replication phase. Green line indicates level of genome wide 398 
significance (p = 5e-8).   399 
 400 
Figure 2: Structural visualization of amino acid variants associated with allergic rhinitis  401 
The surface of the MHC molecule is shown in white, while the backbone of the bound peptide is 402 
shown in dark gray. The amino acid variant in focus is highlighted in red and the peptide binding 403 
pockets of the MHC molecule is indicated with dashed circles and annotated P1-P9. (A) The 404 
amino acid variant with strongest association to AR is HLA-DQB1 His30 (MHC class II), located 405 
close to P6 with a distance of 6Å to the peptide (excluding the peptide side chain). The 406 
protective amino acid variant at this location in relation to AR is hisitidine, whereas the risk 407 
variant is serine. Histidine is positively charged and has a large aromatic ring, whereas serine is 408 
not charged and not aromatic. Therefore, this mutation results in a significant change of the 409 
binding pocket environment. (B) The strongest AR-associated amino acid variation in HLA-B 410 
(MHC class I) is HLA-B AspHisLeu116, located close to P9 with a distance of 7Å to the peptide 411 
(excluding the peptide side chain). The close proximity to the bound peptide for both variants 412 
indicates that they are likely to affect the MHC-peptide interaction and thereby which peptides 413 
are presented. 414 
 415 
Figure 3: Enrichment of allergic rhinitis-associated variants in tissue-specific open 416 
chromatin 417 
Enrichment of 16,531,985 genetic variants associated with allergic rhinitis in 212,120 individuals 418 
(at p < 1e-08 as threshold for marker association) in 189 cell types from ENCODE and 419 
Roadmap epigenomics data. Enrichment and p-value was calculated empirically against a 420 
permuted genomic background using the GARFIELD tool. Red labels indicate blood and blood-421 
related cell-types, grey labels indicate other cell types. Due to number of permutations = 1e7, 422 
empirical p-values reached a minimum ceiling of 1/1e7. FDR threshold = 0.00026. For epstein-423 
Barr virus transformed B-lymphocyte cell types (cell type “GM****”), only most enriched instance 424 
is shown (“B-Lymphocyte”). NHEK = normal human epidermal keratinocytes, HMEC/vHMEC = 425 
mammary epithelial cells, HCM = human cardiac myocytes , WI-38 = lung fibroblast-derived, 426 
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HRGEC = human renal glomerular endothelial cell, HCFaa = Human Cardiac Fibroblasts-Adult 427 
Atrial cell, HMVEC−dBl−Neo = human microvascular endothelial cells, Th1 = T helper cell, type 428 
1, Th2 = T helper cell, type 2. 429 
 430 
Figure 4: Interaction network between drugs and proteins from genes associated with 431 
allergic rhinitis 432 
Grey nodes represent locus genes as well as genes prioritized from e/meQTL and PCHiC 433 
sources, based on genetics association of 16,531,985 markers with allergic rhinitis in 212,120 434 
individuals. Blue nodes represent drugs from the ChEMBL drug database. Edges represent 435 
very-high confidence interactions from the STRING database (for locus-locus interactions) and 436 
drug target evidence (for drug-locus interactions). Red borders indicate genes with protein 437 
products that were significantly enriched in the “Th1 and Th2 Activation” pathway (-log[p-value] 438 
>19.1) from the IPA pathway analysis. 439 
  440 
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Table 1. Association results of index markers (variant with lowest p-value for each locus) previously reported in 441 
relation to AR or other inhalant allergy. Column “Nearest gene” denotes nearest up- and downstream gene (for 442 
intergenic variants with two genes listed), or surrounding gene (for intronic variants with one gene listed), with the 443 
exception of rs5743618, an exonic missense variant within TLR1. EA/OA=effect allele/other allele. P-value is 444 
calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test.  445 
 446 
    Discovery 
Variant Locus Nearest genes EA/OA EAF n (studies) OR 
 
95% conf.int P Het. P 
Known          
rs34004019 6p21.32 HLA-DQB1;HLA-DQA1 G/A 0.27 196,951 (11) 0.89 0.87-0.90 1.00E-30 0.41 
rs950881 2q12.1 IL1RL1;IL1RL1 T/G 0.15 212,120 (18) 0.88 0.87-0.90 1.74E-30 0.91 
rs5743618 4p14 TLR1;TLR10 A/C 0.27 210,652 (17) 0.90 0.89-0.92 4.38E-27 0.70 
rs1438673 5q22.1 CAMK4;WDR36 C/T 0.50 212,120 (18) 1.08 1.07-1.10 3.15E-26 0.26 
rs7936323 11q13.5 LRRC32;C11orf30 A/G 0.48 212,120 (18) 1.08 1.06-1.09 6.53E-24 0.0001 
rs2428494 6p21.33 HLA-B;HLA-C A/T 0.42 195,753 (12) 1.08 1.06-1.09 7.01E-19 0.25 
rs11644510 16p13.13 RMI2;CLEC16A T/C 0.37 212,120 (18) 0.93 0.92-0.95 1.58E-17 0.65 
rs12939457 17q12 GSDMB;ZPBP2 C/T 0.44 212,120 (18) 0.94 0.92-0.95 2.35E-17 0.02 
rs148505069 4q27 IL21;IL2 G/A 0.33 212,120 (18) 1.07 1.05-1.08 2.54E-15 0.02 
rs13395467 2p25.1 ID2;RNF144A G/A 0.28 212,120 (18) 0.94 0.92-0.95 9.93E-15 0.61 
rs9775039 9p24.1 IL33;RANBP6 A/G 0.16 212,120 (18) 1.08 1.06-1.10 2.22E-14 0.40 
rs2164068 2q33.1 PLCL1 A/T 0.49 212,120 (18) 0.94 0.93-0.96 4.21E-14 0.82 
rs2030519 3q28 TPRG1;LPP G/A 0.49 212,120 (18) 1.06 1.04-1.07 1.83E-13 0.12 
rs11256017 10p14 CELF2;GATA3 T/C 0.18 212,120 (18) 1.07 1.05-1.09 2.72E-12 0.60 
rs17294280 15q22.33 AAGAB;SMAD3 G/A 0.25 212,120 (18) 1.07 1.05-1.09 5.97E-12 0.07 
rs7824993 8q21.13 ZBTB10;TPD52 A/G 0.37 212,120 (18) 1.05 1.04-1.07 1.86E-10 0.56 
rs9282864 16p11.2 SULT1A1;SULT1A2 C/A 0.33 208,761 (16) 0.94 0.93-0.96 4.69E-10 0.03 
rs9687749 5q31.1 IL13;RAD50 T/G 0.44 207,604 (16) 1.06 1.04-1.09 1.84E-09 0.19 
rs61977073 14q21.1 TTC6 G/A 0.22 212,120 (18) 1.06 1.04-1.08 5.78E-09 0.05 
rs6470578 8q24.21 TMEM75;MYC T/A 0.28 212,120 (18) 1.05 1.03-1.07 4.36E-08 0.02 
rs3787184 20q13.2 NFATC2;KCNG1 G/A 0.19 207,604 (16) 0.94 0.93-0.96 4.76E-08 0.69 
 447 
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Table 2. Association results of index markers (variant with lowest p-value for each locus) not previously associated with AR reaching a Bonferroni-corrected significance 9 
threshold of 0.05 in the replication phase. Column “Nearest gene” denotes nearest up- and downstream gene (for intergenic variants with two genes listed), or surrounding 0 
gene (for intronic variants with one gene listed), with the exception of rs1504215, an exonic synonymous variant within BACH2. EA/OA=effect allele/other allele. P-value is  
calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test. * Variants also reported associated with a combined 2 
asthma/eczema/hay fever phenotype by Ferreira et al.29 (within +/- 1Mb). 3 
 4 
    Discovery Replication Combined 
Variant Locus Nearest genes EA/ OA EAF n (studies) OR 
95% 
conf.int P 
Het. 
P n (studies) OR 
95% 
conf.int P FWER n (studies) OR 
95% 
conf.int P 
Het. 
P 
rs7717955* 5p13.2 CAPSL; IL7R T/C 0.27 212,120 (18) 0.95 0.93-0.96 1.50E-09 0.24 679,247 (10) 0.93 0.91-0.94 4.09E-25 1.06E-23 891,367 (28) 0.94 0.93-0.95 3.78E-32 0.09 
rs63406760* 12q24.31 CDK2AP1; C12orf65 G/- 0.26 210,652 (17) 0.93 0.91-0.95 5.12E-14 0.91 675,338 (7) 0.95 0.93-0.96 3.27E-12 8.51E-11 885,990 (24) 0.94 0.93-0.95 2.54E-24 0.89 
rs1504215* 6q15 BACH2; GJA10 A/G 0.34 207,604 (16) 0.95 0.94-0.97 1.49E-08 0.02 679,247 (10) 0.95 0.94-0.97 1.99E-11 5.17E-10 886,851 (26) 0.95 0.94-0.96 1.54E-18 0.05 
rs28361986* 11q23.3 CXCR5; DDX6 A/T 0.20 212,120 (18) 0.93 0.91-0.95 1.81E-14 0.87 675,919 (8) 0.94 0.93-0.96 7.92E-11 2.06E-09 888,039 (26) 0.94 0.92-0.95 2.32E-23 0.91 
rs2070902* 1q23.3 AL590714.1; FCER1G T/C 0.25 212,120 (18) 1.06 1.04-1.08 1.03E-10 0.18 679,247 (10) 1.05 1.03-1.06 7.27E-10 1.89E-08 891,367 (28) 1.05 1.04-1.06 6.19E-19 0.23 
rs111371454* 15q15.1 ITPKA; RTF1 G/A 0.21 212,120 (18) 1.06 1.03-1.08 1.65E-07 0.17 675,338 (7) 1.04 1.03-1.06 8.47E-09 2.20E-07 887,458 (25) 1.05 1.03-1.06 1.28E-14 0.22 
rs12509403* 4q24 MANBA; NFKB1 T/C 0.32 212,120 (18) 0.95 0.94-0.97 9.97E-09 0.27 679,247 (10) 0.96 0.95-0.97 1.86E-08 4.84E-07 891,367 (28) 0.96 0.95-0.97 1.17E-15 0.39 
rs9648346* 7p15.1 JAZF1; TAX1BP1 G/C 0.22 207,604 (16) 1.05 1.03-1.07 3.62E-08 0.74 679,247 (10) 1.04 1.03-1.06 1.39E-07 3.63E-06 886,851 (26) 1.05 1.03-1.06 3.30E-14 0.48 
rs35350651* 12q24.12 ATXN2; SH2B3 C/- 0.49 206,136 (15) 1.04 1.03-1.06 6.63E-08 0.60 672,701 (6) 1.04 1.02-1.05 1.41E-07 3.66E-06 878,837 (21) 1.04 1.03-1.05 5.82E-14 0.43 
rs2519093* 9q34.2 ABO; OBP2B T/C 0.20 212,120 (18) 1.06 1.04-1.09 4.96E-11 0.38 675,919 (8) 1.04 1.03-1.06 2.96E-07 7.68E-06 888,039 (26) 1.05 1.04-1.07 2.79E-16 0.61 
rs62257549 3p21.2 VPRBP A/G 0.20 212,120 (18) 0.95 0.93-0.97 7.13E-08 0.45 677,615 (9) 0.96 0.94-0.97 3.37E-07 8.76E-06 889,735 (27) 0.95 0.94-0.97 1.84E-13 0.53 
rs11677002 2p23.2 FOSL2; RBKS C/T 0.45 212,120 (18) 0.96 0.95-0.98 3.80E-07 0.21 679,247 (10) 0.97 0.96-0.98 3.54E-07 9.20E-06 891,367 (28) 0.97 0.96-0.97 7.08E-13 0.36 
rs35597970* 10q24.32 ACTR1A; TMEM180 -/A 0.45 210,652 (17) 1.06 1.04-1.07 1.34E-13 0.96 676,970 (8) 1.03 1.02-1.05 4.37E-07 1.14E-05 887,622 (25) 1.04 1.03-1.05 5.42E-18 0.53 
rs2815765 1p31.1 LRRIQ3; NEGR1 T/C 0.37 212,120 (18) 0.95 0.94-0.97 1.18E-09 0.59 679,247 (10) 0.97 0.95-0.98 6.16E-07 1.60E-05 891,367 (28) 0.96 0.95-0.97 9.45E-15 0.52 
rs11671925* 19q13.11 CEBPA; SLC7A10 A/G 0.17 206,136 (15) 0.94 0.92-0.96 1.80E-08 0.97 677,551 (9) 0.96 0.94-0.98 2.80E-06 7.29E-05 883,687 (24) 0.95 0.94-0.96 5.91E-13 0.60 
rs2461475* 12q24.31 SPPL3; ACADS C/T 0.47 212,120 (18) 1.04 1.02-1.05 9.19E-07 0.97 677,551 (9) 1.03 1.02-1.04 6.52E-06 0.0002 889,671 (27) 1.03 1.02-1.04 3.81E-11 0.83 
rs6738964* 2q36.3 SPHKAP; DAW1 G/T 0.24 212,120 (18) 0.96 0.94-0.97 4.51E-07 0.72 679,247 (10) 0.97 0.96-0.98 4.96E-05 0.0013 891,367 (28) 0.96 0.95-0.97 1.86E-10 0.87 
rs10519067* 15q22.2 RORA A/- 0.13 212,120 (18) 0.93 0.91-0.96 1.78E-09 0.37 442,354 (7) 0.93 0.90-0.96 7.53E-05 0.0020 654,474 (25) 0.93 0.92-0.95 5.53E-13 0.36 
rs138050288* 1p36.23 RERE; SLC45A1 -/CA 0.29 210,652 (17) 1.05 1.04-1.07 5.96E-10 0.71 675,338 (7) 1.03 1.01-1.04 0.0002 0.0046 885,990 (24) 1.04 1.03-1.05 6.62E-12 0.63 
rs7328203 13q14.11 TNFSF11; AKAP11 G/T 0.46 212,120 (18) 1.05 1.03-1.06 5.94E-09 0.90 677,551 (9) 1.02 1.01-1.04 0.0005 0.0134 889,671 (27) 1.03 1.02-1.04 1.28E-10 0.78 
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Methods: 456 
Phenotype definition  457 
Allergic rhinitis (AR) 458 
Cases were defined as individuals ever having a diagnosis or symptoms of AR dependent on 459 
available phenotype definitions in the included studies (Supplementary Table 3 and cohort 460 
recruitment details in Supplementary Note). All relevant ethical regulations were followed as 461 
specified in relation to the individual studies in the Supplementary Note. To maximize numbers 462 
and optimize statistical power, we did not require doctor-diagnosed AR or verification by allergic 463 
sensitization. This approach was confirmed by a sensitivity analysis in 23andMe based on 464 
association with known risk loci for allergic rhinitis (data not shown). Controls were defined as 465 
individuals who never had a diagnosis or symptoms of AR.  466 
 467 
Allergic sensitization (AS) 468 
We considered specific IgE production against inhalant allergens without restriction by 469 
assessment method or type of inhalant allergen. Cases were defined as individuals with 470 
objectively measured sensitization against at least one of the inhalant allergens tested for in the 471 
respective studies, and controls were defined as individuals who were not sensitized against 472 
any of the allergens tested for. We included sensitization assessed by skin reaction after 473 
puncture of the skin with a droplet of allergen extract (SPT) and/or by detection of the levels of 474 
circulating allergen-specific IgE in the blood. The SPT wheal diameter cutoffs were 3 mm larger 475 
than the negative control for cases and smaller than 1 mm for controls. To optimize case 476 
specificity and the correlation between methods, we chose a high cutoff of specific IgE levels for 477 
cases (0.7 IU/ml) and a low cutoff for controls (0.35 IU/ml).  478 
 479 
Non-allergic rhinitis (NAR) 480 
Case were defined as individuals with current allergic rhinitis symptoms (within the last 12 481 
months) and no allergic sensitization (negative specific IgE (< 0.35 IU/mL) and/or negative skin 482 
prick test (< 1 mm) for all allergens and time points tested) 483 
Controls were defined as individuals never having symptoms of allergic rhinitis and no allergic 484 
sensitization (negative specific IgE (< 0.35 IU/mL) and/or negative skin prick test (< 1 mm) for all 485 
allergens and time points tested) 486 
 487 
For all 3 phenotypes, we combined data from children and adults but chose a lower age limit of 488 
6 years, as allergic rhinitis and sensitization status at younger ages show poorer correlation with 489 
status later in life, both owing to transient symptoms/sensitization status and frequent 490 
development of symptoms/sensitization during late childhood. 491 
GWAS QC and cohort summary data harmonization 492 
For AR, AS, and NAR, each cohort imputed their data separately using the 1000 Genomes 493 
Project (1KGP) phase 1, version 3 release, and conducted the genome-wide association 494 
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analysis adjusted for sex and if necessary for age and principal components (Supplementary 495 
Table 3). All studies included individuals of European descent, except Generation R and 496 
RAINE, comprising a mixed, multi-ethnic population. We utilized EasyQC v. 9.236 for quality 497 
control and marker harmonization for cohort-level meta-GWAS summary files. Cohort data was 498 
harmonized to genome build GRCh37 and checked against 1KGP phase 3 reference allele 499 
frequencies for processing problems. GWAS summary “karyograms” were visually inspected to 500 
catch cohorts with incomplete data. Distributions of estimate coefficients and errors, as well as 501 
“Standard error vs. sample size”- and “p value vs. z-score” plots were inspected for each cohort 502 
for systematic errors in statistical models. Ambiguous markers that were non-unique in terms of 503 
both genomic position and allele coding were removed. A minimum imputation score of 0.3 (R2) 504 
or 0.4 (proper_info) was required for markers. A minimum minor allele count of 7 was required 505 
for each marker in each cohort, as suggested by the GIANT consortium and EasyQC. 506 
 507 
Meta-Analysis 508 
For AR, AS, and NAR, meta-analysis for the discovery phase was conducted using GWAMA37 509 
with an inverse variance weighted fixed-effect model with genomic control correction of the 510 
individual studies. Each locus is represented by the variant showing the strongest evidence 511 
within a 1Mb buffer. Loci were inspected visually by plotting genomic neighbourhood and 512 
coloring for 1KGP r2 values. From the pool of genomewide significant markers in the discovery, 513 
one locus with index marker rs193243426 without a credible LD structure was removed from 514 
further analysis (Supplementary Fig. 10). Heterogeneity was assessed with Cochran’s Q test. 515 
Meta-analysis of replication candidates from the AR discovery phase was carried out using R 516 
version 3.4.0, and the meta package version 4.8-2 with an inverse variance weighted fixed-517 
effect model. For a subset of markers, cohorts reported suitable proxies (r2>0.85), where 518 
followed-up markers were not present or had insufficient imputation or genotyping quality 519 
(Supplementary Table 25).  520 
Gene set overrepresentation analysis, discovery phase 521 
To facilitate selection of biologically relevant discovery candidates in the sub-genomewide 522 
significant stratum (5e-8 < p < 1e-6), we employed a custom gene set overrepresentation 523 
analysis algorithm implemented in R, with a scoring and permutation regime modeled after 524 
MAGENTA.38 Genes with lengths less than 200bp, with copies on multiple chromosomes, and 525 
with multiple copies on the same chromosome more than 1Mb apart were removed from 526 
analysis. Gene models (GENCODE v 19) were downloaded from the UCSC Table Browser,39 527 
and expanded 110 kb upstream, and 40 kb downstream, similar to MAGENTA. The HLA region 528 
was excluded from analysis (chromosome 6: 29,691,116-33,054,976). Similar to MAGENTA, 529 
gene scores were adjusted for number of markers per gene, gene width, recombination 530 
hotspots, genetic distance, and number of independent markers per gene, all with updated data 531 
from UCSC Table Browser. For the gene set overrepresentation permutation calculation, gene 532 
sets from the MSigDB collections c2, c3, c5, c7, and hallmark, were included.40 A MAGENTA-533 
style enrichment cutoff at 95% was used. Gene sets with FDR<0.05 were considered. 534 
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Conditional analyses 535 
To identify additional independent markers at each discovery genomic region, we used 536 
Genome-wide Complex Trait Analysis (GCTA) v. 1.26.0.41 Within a window of +/- 1Mb of each 537 
discovery phase index marker, all markers were conditioned on the index using the --cojo-cond 538 
feature of GCTA with default parameters. Plink v. 1.90b3.4242 was used to calculate r2 for GCTA 539 
with the UK10K full genotype panel43 as reference. A total of 42 of 52 markers from the full 540 
discovery phase were present in UK10K. As a MAF-dependent inflation of conditional p-values 541 
was observed (data not shown), only conditional markers with MAF >= 10% were selected. 542 
Locus definition and credible sets for VEP annotation 543 
Discovery loci were defined as index markers extended with markers in LD (r2 >= 0.5), based on 544 
the 1KGP phase 3. Protein coding gene transcript models (GENCODE v. 24) were downloaded 545 
from the UCSC Table Browser, and nearest upstream, downstream, as well as all genes within 546 
the extended loci were annotated. 547 
Credible sets for each locus were calculated using the method of Morris, A.P44. 548 
LD was calculated for each discovery index variant within +/- 500 kb, and markers with r2<0.1 549 
were excluded. For the remaining markers, the Bayesian Factor (ABF) values and the posterior 550 
probabilities (PostProb) were calculated, and cumulative posterior probability values were 551 
generated based ranking markers on ABF. Finally, variants were included in the 99% credible 552 
set until the cumulative posterior probability was greater or equal than 0.99. 553 
Credible sets for each loci was annotated with information on mutation impact in coding regions 554 
using the Variant effect Prediction (VeP) REST API45, exporting only the nonsynonymous 555 
substitutions. 556 
GWAS catalogue lookup 557 
For annotation of markers with identification in previous GWA studies, the GWAS catalog was 558 
downloaded from NHGRI-EBI (v.1.0.1, 2016-11-28). For this analysis, AR loci were lifted from 559 
genomic build GRCh37 to GRCh38, and extended with +/- 1Mb in each direction before being 560 
overlapped with GWAS catalog annotations. Relevant GWAS catalog overlap traits were binned 561 
into trait groups “Allergic Rhinitis”, “Asthma”, “Autoimmune”, “Eczema”, “Infectious Diseases”, 562 
“Lung-related Traits”, and “Other allergy”. A million random genomic intervals of the same length 563 
(2Mb) were obtained to generate a background overlap distribution, and p-values were 564 
calculated from this background. 565 
HLA classical allele analysis 566 
Analyses of imputed classical HLA-alleles were performed in the 23andMe study (AR discovery 567 
population) comprising 49,180 individuals with allergic rhinitis and 124,102 controls.  568 
HLA imputation was performed with HIBAG.46 We imputed allelic dosage for HLA-A, B, C, 569 
DPB1, DQA1, QB1, and DRB1 loci at four-digit resolution using the default settings of HIBAG 570 
for a total of 292 classical HLA alleles.  571 
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Using an approach suggested by P. de Bakker,47 we downloaded the files that map HLA alleles 572 
to amino acid sequences from https://www.broadinstitute.org/mpg/snp2hla/ and mapped our 573 
imputed HLA alleles at four-digit resolution to the corresponding amino acid sequences; in this 574 
way we translated the imputed HLA allelic dosages directly to amino acid dosages. We encoded 575 
all amino acid variants in the 23andMe European samples as 2395 bi-allelic amino acid 576 
polymorphisms as previously described.48  577 
Similar to the SNP imputation, we measured imputation quality using r2, which is the ratio of the 578 
empirically observed variance of the allele dosage to the expected variance assuming Hardy-579 
Weinberg equilibrium.  580 
To test associations between imputed HLA alleles, amino acid variants, and phenotypes, we 581 
performed logistic regression using the same set of covariates used in the SNPbased GWAS. 582 
We applied a forward stepwise strategy, within each type of variant, to establish statistically 583 
independent signals in the HLA region. Within each variant type, we first identified the most 584 
strongly associated signals (lowest p-value) and performed forward iterative conditional 585 
regression to identify other independent signals. All analyses were controlled for sex and five 586 
principal components of genetic ancestry. The p-values were calculated using a likelihood ratio 587 
test.  588 
 589 
Structural visualization of amino acid variants 590 
Structural visualization of amino acid variants was performed for the strongest associated 591 
variants in HLA-DQB1 (position 30) and HLA-B (position 116), respectively (Supplementary 592 
Table 10) and were made using X-ray structures from the Protein Data Bank (PDB).49 To find 593 
the best structure we used the specialized search function in the Immune Epitope Database,50 594 
selecting only X-ray crystalized structures for the specific MHC classes HLA-DQB1 (class II) 595 
and HLA-B (class I). Using this criterion, we found 17 crystallized structures for HLA-DQB1 and 596 
164 structures for HLA-B. From these lists, we selected the structure with the lowest resolution 597 
and the amino acids encoded by the reported top SNPs. The PDB accession code for the 598 
selected structures was 4MAY51 for HLA-DQB1 and 2A8352 for HLA-B and both structures were 599 
visualized using PyMOL v. 1.8.2.1 (http://www.pymol.org). Furthermore, we used PyMOL to 600 
measure intra-molecular distances from the side chain of the amino acids associated with 601 
allergic rhinitis to the C atoms in the peptide. This distance measure was chosen to 602 
accommodate the possibility for different amino acids in the peptide. In order for two amino 603 
acids to interact the distance should be approximately 4Å or less. We measured distances of 6Å 604 
(HLA-DQB1) and 7Å (HLA-B). However these distances do not include the peptide side chains 605 
which range from 1.5 Å – 8.8 Å. Therefore, we estimate that physical interaction between the 606 
amino acids encoded by the top SNPs and the peptide is likely. 607 
Genetic heritability and genetic correlation 608 
For calculating genetic heritability and genetic correlation between AR and AS, as well as 609 
between clinical cohorts and 23andMe within AR, we utilized the LD score regression based 610 
method as implemented by LDSC v. 1.0.45,53 Population prevalence was set to 10% for AR and 611 
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AS. Genetic correlation analysis between AR, AS and published GWAS studies was carried out 612 
using the LDHUB platform v. 1.3.154 against all traits, but excluding Metabolites55.    613 
eQTL sources and analysis 614 
From GTEx V6p56, all significant variant-gene cis eQTL pairs for whole blood, lung, and EBV-615 
transformed lymphocytes were downloaded from https://gtexportal.org, and carried forward in 616 
analysis. From Westra et al.57, both cis and trans eQTLs in whole blood were downloaded, and 617 
variant-gene pairs with FDR < 0.1 were carried forward in analysis. From Fairfax et al.58, cis 618 
eQTLs from monocytes and B cells were downloaded, and variant-gene pairs with FDR < 0.1 619 
were carried forward in analyses. From Bonder et al.58, meQTLs from whole blood were 620 
downloaded, and variant-probe pairs with FDR < 0.05 were carried forward in analyses. From 621 
Nicodemus-Johnson et al.59, cis eQTLs and meQTLs from lung were downloaded, and variant-622 
gene pairs with FDR < 0.1 were carried forward in analyses. From Momozawa et al. [in press, 623 
personal correspondence], cis eQTLs from blood cell types CD14, CD15, CD19, CD4, and CD8 624 
were downloaded, and variant-gene pairs with a weighted correlation of >= 0.6 were carried 625 
forward to analysis. For supplementary table 14 priority genes, protein coding information was 626 
downloaded from the UCSC Table Browser, using the “transcriptClass” field from the 627 
“wgEncodeGencodeAttrsV24lift37” table. 628 
Promoter Capture Hi-C Gene Prioritisation 629 
To assess spatial promoter interactions in the discovery set, we performed a Capture Hi-C 630 
Gene Prioritisation (CHIGP) as described in Javierre et al.60 and 631 
https://github.com/ollyburren/CHIGP using recommended settings and data sources: 0.1cM 632 
recombination blocks, 1KGP EUR reference population, coding markers from the GRCh37 633 
Ensembl assembly and the CHICAGO-generated61 Promoter Capture Hi-C peak matrix data 634 
from 17 human primary blood cell types supplied in the original paper. The resulting protein-635 
coding prioritized genes (gene score > 0.5) were used in the downstream network analysis, 636 
from cell types "Fetal thymus", "Total CD4 T cells", "Activated total CD4 T cells", "Non-activated 637 
total CD4 T cells", "Naive CD4 T cells", "Total CD8 T cells", "Naive CD8 T cells", "Total B cells", 638 
"Naive B cells", "Endothelial precursors", "Macrophages M0", "Macrophages M1", 639 
"Macrophages M2", "Monocytes", and "Neutrophils". 640 
Gene set overrepresentation analysis of known and replicating novel loci 641 
All high-confidence gene symbols from eQTL and meQTL sources, PCHiC, as well as genes 642 
(models extended 110kb upstream, and 40kb downstream) within each r2-based loci definition  643 
from known and replicating novel loci were input into the pathway-based set over-representation 644 
analysis module of ConsensusPathDB (CPDB) database and tools62 with 229 of 277 gene 645 
identifiers translated. In addition, these same symbols were used for Ingenuity pathway analysis 646 
(IPA; www.ingenuity.com; a curated database of the relationships between genes obtained from 647 
published articles, and genetic and expression data repositories) to identify biological pathways 648 
common to genes. IPA determines whether the associated genes are significantly enriched in a 649 
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specific biological function or network by assessing direct interactions. We assigned significance 650 
if right-tailed Fisher’s exact test p-value < 0.05. 651 
eQTL/meQTL, PCHiC and locus gene intersections were visualized using the UpSetR package 652 
(v1.3.2) 63. 653 
Tissue overrepresentation 654 
To assay the enrichment of variants associated with AR in tissue specific gene expression sets, 655 
we utilized the DEPICT enrichment method64, using a p-value threshold of 1e-5, and standard 656 
settings.    657 
Enrichment of regulatory regions 658 
To assay the enrichment of variants associated with AR in regions of open chromatin and 659 
specific histone marks, we utilized the GWAS Analysis of Regulatory or Functional Information 660 
Enrichment with LD correction (GARFIELD v. 1) method65. In essence, GARFIELD performs 661 
greedy pruning of GWAS markers (LD r2 > 0.1) and then annotates them based on functional 662 
information overlap. Next, it quantifies Fold Enrichment (FE) at various GWAS significance 663 
cutoffs and assesses them by permutation testing, while adjusting for minor allele frequency, 664 
distance to nearest transcription start site and number of LD proxies (r2 > 0.8). GARFIELD was 665 
run with 10,000,000 permutations, and otherwise default settings. 666 
PARF 667 
Population-attributable risk fractions (PARFs) were estimated from B58C, a general-population 668 
sample with participant ages 44-45 years also contributing to the discovery stage. The genetic 669 
risk score was calculated by applying the pooled per-allele coefficients (ln(OR) values) from the 670 
AR discovery set to the number of higher-risk alleles of each of the 41 established (known 671 
genome-wide significant and novel replicated loci), one SNP per locus. Because there were no 672 
individuals observed with zero higher-risk alleles, the prevalence of sensitization for individuals 673 
in the lowest decile of the genetic risk score distribution was used to derive PARF estimates on 674 
the assumption that this 10% of the population was unexposed. This method has the advantage 675 
that it does not predict beyond the bounds of the data, but its results are conservative. The 676 
PARF was then derived (with 95% confidence interval) by expressing the difference between 677 
the observed prevalence and the predicted (unexposed) prevalence as a percentage of the 678 
observed prevalence. PARFs were estimated using the 41 AR loci in relation to AR, AS and 679 
NAR, respectively. 680 
Protein network and drug interactions 681 
In order to analyse protein-protein-drug interaction networks, STRING (V10)66 was used. Protein 682 
network data (9606.protein.links.v10.txt.gz) and protein alias data (9606.protein.aliases.v10.txt) 683 
files were downloaded from the string db website [http://string-db.org/]. GWAS hits stratified on 684 
‘all’, ‘blood’ and ‘lung’ were converted to Ensembl protein ids using the protein alias data. The 685 
interactors were subsequently identified using the link data at a ‘high confidence cutoff of >0.7’ 686 
 7 
as described in the STRING FAQ. The interactor Ensembl protein ids were then converted to 687 
UniProt gene names and both hits and interactors were then analyzed for interactions with FDA 688 
approved drugs using the ChEMBL Database v. 2267 API via Python (v. 2.7.12). Lastly, stratified 689 
networks consisting of GWAS hits connected to interactors and drugs connected to both GWAS 690 
hits and interactors were visualised using GGraph (v. 1.0.0), iGraph (v. 1.0.1), TidyVerse (v. 691 
1.1.1) under R (v. 3.3.2). 692 
Data availability 693 
Genome-wide results, excluding 23andMe, are available on request through the corresponding 694 
author. The full GWAS summary statistics for the 23andMe discovery data set will be made 695 
available through 23andMe to qualified researchers under an agreement with 23andMe that 696 
protects the privacy of the 23andMe participants. Please contact David Hinds 697 
(dhinds@23andme.com) for more information and to apply to access the 23andMe data. A Life 698 
Sciences Reporting Summary is available for this paper. 699 
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